{"entity":{"id":"chu-habib-bourguiba-sfax","kind":"institution","name":"Hôpital Habib Bourguiba, Sfax","aka":["Habib Bourguiba Hospital, Sfax","CHU Habib Bourguiba Sfax"],"tldr":"A hospital in Sfax, in southern Tunisia, whose radiotherapy department has two linear accelerators, a cobalt unit and two brachytherapy units. It is a site for an international breast cancer trial.","summary":"IAEA DIRAC's equipment report, read on 11 November 2026 with the entry last updated in 2024, lists Habib Bourguiba Hospital in Sfax with two linear accelerators, one cobalt-60 unit, two brachytherapy units and a CT scanner. ClinicalTrials.gov lists Habib Bourguiba Hospital, Sfax, as a site of the trial of inavolisib with pertuzumab and trastuzumab in PIK3CA-mutated HER2-positive breast cancer (NCT05894239). OnCo could not read a site of the hospital's own.","asOf":"2026-11-11","links":[{"label":"IAEA DIRAC: radiotherapy centres and equipment (read 11 November 2026)","url":"https://dirac.iaea.org/Data/CountriesLight"},{"label":"ClinicalTrials.gov NCT05894239: site list","url":"https://clinicaltrials.gov/study/NCT05894239"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-salah-azaiez","chu-farhat-hached-sousse"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sfax","country":"TN","lat":34.74,"lng":10.748,"institutionType":"hospital","programs":["Radiotherapy and brachytherapy (IAEA DIRAC)"]},"route":"/institutions/chu-habib-bourguiba-sfax/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"chu-farhat-hached-sousse","kind":"institution","name":"Centre Hospitalier Universitaire Farhat Hached, Sousse","route":"/institutions/chu-farhat-hached-sousse/"},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/"}],"trial":[{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/"}]}}